The ceremony began with opening remarks from Prof. Raymond Wai-Yeung Wong, Prof. Simon Lee, Dr. Miguel Garcia (CEO of TechnoPhage SA), and Prof. Yuqiang Wang (founder of Guangzhou Magpie Pharmaceutical Co., Ltd) .
AIM Pharmaceutical International Limited signed strategic cooperation agreements with TechnoPhage SA, a Portuguese biotechnology company, and Guangzhou Magpie Pharmaceutical Co., Ltd. to collaborate on new drug research and development for neurodegenerative diseases. The parties will establish a NewCo model to advance clinical trials of the AIM-01-PD series of drugs in the U.S. and Europe, targeting mild to moderate Parkinson's disease and its complications. AIM Pharmaceutical will also promote the registration and marketing of TechnoPhage's new nutrient product C1 in China for the prevention and treatment of neurodegenerative diseases.
During the seminar, Prof. Simon LEE provided updates on the clinical trials of the innovative drug AIM-01-PD for neurodegenerative diseases, as well as the development of the new nutrient CogniUP and AIM Pharmaceutical's natural product discovery and screening platform.
The seminar gathered leading scholars and industry experts in natural medicines to discuss recent advancements in natural product research, the journey of drug discovery, and innovative therapies for unmet medical needs.
This event served as both an academic exchange platform and a starting point for international collaboration. Attendees explored ways to advance the biopharmaceutical field through innovative cooperation to tackle global health challenges.
